Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Current Drug Metabolism
Title:Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Volume: 15 Issue: 2
Author(s): Vojtech Huser, Samuel G. Johnson, Marc S. Williams, Mary V. Relling, Dan Roden, C. Michael Stein, Rachel F. Tyndale, Jesse J. Swen, Mia Wadelius, Stuart A. Scott, Kristine R. Crews, Otito F. Iwuchukwu, Ming Ta Michael Lee, Kelly E. Caudle, Robert R. Freimuth, Jose A.G. Agundez, Matthias Schwab, Caroline F. Thorn, Katrin Sangkuhl, Ellen M. McDonagh, Li Gong, Michelle Whirl-Carrillo, Daniel J. Muller, James M. Hoffman and Teri E. Klein
Affiliation:
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Export Options
About this article
Cite this article as:
Huser Vojtech, Johnson G. Samuel, Williams S. Marc, Relling V. Mary, Roden Dan, Stein Michael C., Tyndale F. Rachel, Swen J. Jesse, Wadelius Mia, Scott A. Stuart, Crews R. Kristine, Iwuchukwu F. Otito, Michael Lee Ta Ming, Caudle E. Kelly, Freimuth R. Robert, Agundez A.G. Jose, Schwab Matthias, Thorn F. Caroline, Sangkuhl Katrin, McDonagh M. Ellen, Gong Li, Whirl-Carrillo Michelle, Muller J. Daniel, Hoffman M. James and Klein E. Teri, Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 2014; 15 (2) . https://dx.doi.org/10.2174/1389200215666140130124910
DOI https://dx.doi.org/10.2174/1389200215666140130124910 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate
Current Neuropharmacology Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract
Current Molecular Pharmacology Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials CoMFA and CoMSIA Studies on Aryl Carboxylic Acid Amide Derivatives as Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Current Computer-Aided Drug Design Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Costing Human Rights and Community Support Interventions as a Part of Universal Access to HIV Treatment and Care in a Southern African Setting
Current HIV Research No Association Between GRM3 and Japanese Methamphetamine- Induced Psychosis
Current Neuropharmacology Physicochemical Strategies for Inhibition of Amyloid Fibril Formation: An Overview of Recent Advances
Current Medicinal Chemistry Can MDMA Play a Role in the Treatment of Substance Abuse?
Current Drug Abuse Reviews Increased Arterial Stiffness is Associated with Poor Collaterals in Acute Ischemic Stroke from Large Vessel Occlusion
Current Neurovascular Research Quantitative Structure-Retention-Pharmacokinetic Relationship Studies
Drug Metabolism Letters New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents
Medicinal Chemistry